《INNOCARE:ANNUALRESULTSANNOUNCEMENTFORTHEYEARENDED31DECEMBER2025.pdf》由会员分享,可在线阅读,更多相关《INNOCARE:ANNUALRESULTSANNOUNCEMENTFORTHEYEARENDED31DECEMBER2025.pdf(112页珍藏版)》请在三个皮匠报告上搜索。
1、 1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in rel
2、iance upon the whole or any part of the contents of this announcement.InnoCare Pharma Limited諾誠健華醫藥有限公司(Incorporated in the Cayman Islands with limited liability)(Stock Code:9969)ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2025The board(the“Board”)of directors(the“Directors”)of InnoCar
3、e Pharma Limited(the“Company”,and together with its subsidiaries,the“Group”)is pleased to announce the audited consolidated results of the Group for the year ended 31 December 2025(the“Reporting Period”),together with the comparative figures for the year ended 31 December 2024.The consolidated finan
4、cial statements of the Group for the Reporting Period have been reviewed by the Board and Audit Committee of the Company and confirmed by the Companys auditors.In this announcement,“we”,“us”and“our”refer to the Company and where the context otherwise requires,the Group.Certain amount and percentage
5、figure included in this announcement have been subject to rounding adjustments or have been rounded to one or two decimal places,as appropriate.Any discrepancies in any table,chart or elsewhere totals and sums of amounts listed therein are due to rounding.Unless otherwise defined herein,capitalised
6、terms used in this announcement shall have the same meanings as those defined in the Prospectus.2 FINANCIAL HIGHLIGHTS20252024RMB000RMB000Revenue2,374,9061,009,448Cost of sales(191,113)(138,441)Gross profit2,183,793871,007Other income and gains262,183210,828Selling and distribution expenses(579,956)